Tag Archives: LIXXF

Hot Stocks To Invest In Right Now

President Trump’s seemingly top priority is to keep the promises he made on the campaign trail and remake the federal government.

But judging from his first set of budget proposals to Congress, doing so is likely to come at the expense of those in need.

Advocates for lower-income Americans see the president’s proposed spending cuts in his “skinny” budget as an assault.

“This isn’t a budget that will make America great again. It’s a budget that will increase hardship and poverty,” said Robert Greenstein, president of the liberal Center on Budget and Policy Priorities.

When asked at a press briefing if the president’s spending blueprint is hard-hearted because it would cut programs that help low-income children and seniors, White House Budget Director Mick Mulvaney said he felt it was “as compassionate as you can get.”

“You’re only focusing on half of the equation, right? You’re focusing on recipients of the money. We’re trying to focus on both the recipients of the money and the folks who give us the money in the first place. [I]t’s fairly compassionate to go to them and say, look, ‘We’re not going to ask you for your hard-earned money anymore … unless we can guarantee to you that that money is actually being used in a proper function.”

Hot Stocks To Invest In Right Now: Lumber Liquidators Holdings, Inc(LL)

Advisors’ Opinion:

  • [By Daniel Miller]

    If you remember about a year ago, the Centers for Disease Control and Prevention let the world know that consumers who had purchased the China-produced flooring from Lumber Liquidators Holdings (NYSE:LL) were roughly three times more likely to fall ill with cancer. That rate was much higher than earlier calculations following the 2015 broadcast by CBS’ 60 Minutes.The stock shed much of its value since the 2015 airing, but rebounded 17% on Tuesday after it reported a narrower-than-expected loss during the fourth quarter, offering investors a slight amount of hope going forward.

  • [By Peter Graham]

    Small cap hardwood flooring stockLumber Liquidators Holdings Inc (NYSE: LL) reportedQ2 2017 earnings before the market opened this morning with better than expected earnings sending shares soaring as the Company went into earnings with short interest of 24.68% according to Highshortinterest.com. Net sales increased10.7% to $263.5 million as net sales in comparable stores increased 8.8% driven by a 5.3% increase in the number of customers invoiced and a 3.5% increase in the average sale. Merchandise sales in comparable stores grew 6.1% in the quarter whilenet sales in non-comparable stores increased $4.4 million. The Company did not open any stores during the second quarter of 2017 with the total store count remaining at 385 as of June 30, 2017. Net income was $4.5 million versusa net loss of $12.2 million for the first profit in the wake of a 2015 “60 Minutes” report that claimed the Companys laminate flooring contained high levels of cancer-causing formaldehyde.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap hardwood flooring stockLumber Liquidators Holdings Inc (NYSE: LL) is scheduled for before the market opens onTuesday (February 21th). Lumber Liquidators Holdingshad been ahighflying stock until the middle of 2013 when shares were hit be allegations that the companys flooring products contained illegal levels of formaldehyde. Shares then took another hit on reports that the Department of Homeland Security andthe USFish and Wildlife Servicehad executed a sealed court-issuedsearch/raid on theheadquarters for possible sourcing violations.Lumber Liquidators Holdingslater won a favorable ruling in a California lawsuit filed under the state’s Proposition 65 covering cancer-causing chemicals and agreed to pay $2.5 million (without admitting wrongdoing) to settle a civil matter with the California Air Resources Board.

Hot Stocks To Invest In Right Now: PetroChina Company Limited(PTR)

Advisors’ Opinion:

  • [By Money Morning News Team]

    PetroChina Co. Ltd. (NYSE ADR: PTR) is China’s largest oil company with a market cap of $216.52 billion. PTR is partially owned by the Chinese government.

Hot Stocks To Invest In Right Now: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

Hot Stocks To Invest In Right Now: (SMPQY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The majority owner is Sun Pharma (OTC:SMPQY) (the largest drug business in India). There have been a number of articles that have outlined Sun Pharma and its quest for Taro, but it makes a lot of sense for Sun to want to own all – and not just the majority – of Taro. One big reason is that owning all of Taro means that any investments that Sun makes with Taros $1.2 billion cash hoard will not be diluted by the presence of minority shareholders. Another reason that Sun likely wants Taro is simply because it is very cheap right now. Sun is run by its founder and majority shareholder, Dilip Shanghvi, who is sort of a pharmaceutical value investor who has opportunistically made acquisitions and investments over time, building his firm starting with a loan of $200 in the early 1980s to the multi-billion business it is today.

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ

Top 10 Undervalued Stocks To Invest In Right Now

Over the past year, the performance of T. Rowe Price Blue Chip Growth (TRBCX has underscored why it pays to sit tight when a fund with a superior long-term record hits a speed bump. In 2016, as investors turned away from shares of the fast-growing, large-capitalization stocks that Blue Chip targets in favor of more-undervalued fare, the fund lagged the stock market dramatically. Stocks that had previously buoyed the fund, such as Amazon.com and Facebook, were suddenly a drag, says manager Larry Puglia. And energy and utility stockssectors that Blue Chip tends to ignoreperformed exceptionally well.

See Also: Kip 25 Best No-Load Mutual Funds 2017

But these kinds of style shifts dont last forever. Large-cap growth stocks, led by the technology sector, are rebounding this year, and Blue Chip is benefiting. In the first three months of 2017, the fund returned 10.4%, beating Standard & Poors 500-stock index by 4.3 percentage points. Over the past 12 months, Blue Chip, a member of the Kiplinger 25, outpaced the index by nearly a full percentage point. (Prices and returns are through March 31)

Top 10 Undervalued Stocks To Invest In Right Now: L-3 Communications Holdings, Inc.(LLL)

Advisors’ Opinion:

  • [By Paul Ausick]

    Five teams are expected to compete for the contract: Boeing Co. (NYSE: BA) has joined with Saab to offer a clean-sheet design; Northrop Grumman Corp. (NYSE: NOC) has teamed up with BAE Systems and L-3 Communications Holdings Inc. (NYSE: LLL) on another clean-sheet design; Lockheed Martin Corp. (NYSE: LMT) and Korea Aerospace Industries (KAI) are going with a modified KAI T-50; Raytheon Corp. (NYSE: RTN) has joined with Italy’s Leonardo and Canada’s CAE Inc. (NYSE: CAE) on a version of Leonardo’s M-346 trainer that it calls the T-100; and privately held Sierra Nevada has partnered with Turkish Aerospace Industries (TAI) on another clean-sheet design.

  • [By Peter Graham]

    A long term performance chart shows ViaSat, Inc plus mid to large cap communications stockslikeHarris Corporation (NYSE: HRS) and L-3 Communications Holdings, Inc (NYSE: LLL)had been moving in tandem until last yearwhile small cap Gogo Inc has underperformed:

  • [By Peter Graham]

    Headquartered in New York City, large cap L3 Technologies Inc (NYSE: LLL) employs approximately 38,000 people worldwide and is a leading provider of a broad range of communication, electronic and sensor systems used on military, homeland security and commercial platforms. L3 is also a prime contractor in aerospace systems, security and detection systems, and pilot training. The Company reported 2016 sales of $10.5 billion.

Top 10 Undervalued Stocks To Invest In Right Now: Salesforce.com Inc(CRM)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cloud-software leader Salesforce (CRM) – my Top Pick for 2017 among large cap technology stocks — remains well positioned to reap the benefits of the transition away from on-premises solutions.

  • [By WWW.THESTREET.COM]

    “There are two things that mess up your relationships, it’s anger and fear,” explains Robbins. Robbins points to Salesforce (CRM) CEO Marc Benioff as being a total giver, which has set him up for success in business.

  • [By Peter Graham]

    On the earnings call, Ellison noted that the company had surpassed Salesforce.com, inc (NYSE: CRM) in annualized recurring cloud revenue: We are now well on our way to passing them and becoming number one in the enterprise SaaS market.”

Top 10 Undervalued Stocks To Invest In Right Now: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

Top 10 Undervalued Stocks To Invest In Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

Top 10 Undervalued Stocks To Invest In Right Now: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

Top 10 Undervalued Stocks To Invest In Right Now: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Undervalued Stocks To Invest In Right Now: Cemex S.A.B. de C.V.(CX)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cemex SAB de CV (CX) is very interesting at these levels as it seems the market is pricing in a stronger dollar (thereby reducing revenue) and thus lower growth.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.4% Friday to post a new 52-week low of $7.41 after closing at $7.59 on Thursday. The 52-week high is $10.37. Volume was around 8.8 million, about 15% below the daily average of around 9.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.7% Thursday to post a new 52-week low of $7.57 after closing at $7.78 on Wednesday. The 52-week high is $10.37. Volume was around 6.8 million, about 15% below the daily average of around 8.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 1.8% Wednesday to post a new 52-week low of $7.16 after closing at $7.29 on Tuesday. The 52-week high is $10.37. Volume was around 7 million, about 20% below the daily average of around 9.5. The Mexico-based cement company had no specific news.

Top 10 Undervalued Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

Top 10 Undervalued Stocks To Invest In Right Now: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Craig Jones]

    JPMorgan’s analyst Michael Gambardella downgraded Century Aluminum Co (NASDAQ: CENX) from Overweight to Neutral and reduced its price target from $22 to $14.50, citing alumina cost headwinds as the main reason for the downgrade.

Top 10 Undervalued Stocks To Invest In Right Now: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

Top 5 Clean Energy Stocks To Watch For 2018

Amazon (AMZN) reported mixed quarterly results last week, posting a healthy top line beat of $37.95B vs FactSet’s $37.2B consensus, while the bottom line EPS of $0.40 came in significantly lower than the Street’s $1.41 expectation. In light of the sizable earnings miss, some familiar questions are being raised about a deceleration quarterly sales growth rate increase, operating margin pressures and increasing competition in the Amazon Web Services (AWS) space. Additionally, the wide operating income guidance (projecting between -$400 Million and +$300 Million), did little to clarify how management expects Q3 to project. While these concerns have merit, we believe that Amazon is continuing to execute their game-plan, as their strong revenue growth (+25% y/y), justifies their occasional EPS misses. AMZN has historically shown a willingness to spend money and more importantly, the ability to monetize those investments in a way that creates value for their shareholders.

One area of unquestioned success for Amazon is the continued perceived value it delivers to its users, which leads to its overall high customer satisfaction. Amazon was first measured by the American Customer Satisfaction Index (ACSI) in 2000 and has been the highest rated company in the Internet Retail category in 15 of the 17 subsequent years, including the last 10 straight. AMZN is also the largest position in the American Customer Satisfaction Core Alpha ETF (ACSI).

Top 5 Clean Energy Stocks To Watch For 2018: Intec Pharma Ltd.(NTEC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Intec Pharma Ltd (NASDAQ: NTEC) shares dropped 25 percent to $5.57. Intec Pharma reported a Q3 loss of $0.29 per share.

    Shares of Diplomat Pharmacy Inc (NYSE: DPLO) were down 23 percent to $14.71. Diplomat Pharmacy agreed to buy LDI Integrated Pharmacy Services. Baird downgraded Diplomat Pharmacy from Outperform to Neutral.

  • [By Lisa Levin]

    Intec Pharma Ltd (NASDAQ: NTEC) shares were also up, gaining 14 percent to $5.53. Intec Pharma priced 10.6 million share offering at $4.70 per share.

Top 5 Clean Energy Stocks To Watch For 2018: Veeva Systems Inc.(VEEV)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Elite Opportunity Pronewsletter suggested mid cap global life sciencescloud-based software solutions stock Veeva Systems Inc (NYSE: VEEV) as a bullish long trade for investors who have patience:

  • [By Brian Stoffel]

    HR and payroll specialist Paycom Software (NYSE:PAYC), mortgage software provider Ellie Mae (NYSE:ELLI), and cloud computing king for drug companies Veeva Systems (NYSE:VEEV) are the three best software companies you could buy in 2017. They share three key traits that any investor can love: high switching costs, blazing growth rates, and founders or CEOs with lots of skin in the game.

  • [By Brian Stoffel]

    Last week, management at Veeva Systems (NYSE:VEEV) reported earnings that investors have become accustomed to. In fact, shareholders have been downright spoiled: both the top and bottom lines came in ahead of expectations; annual sales growth from Veeva’s non-CRM division came in at a blistering 113%.

  • [By Peter Graham]

    Mid cap global life sciencescloud-based software solutions stock Veeva Systems Inc (NYSE: VEEV) reported fiscal Q1 2018 earnings after the market closed yesterday with earningsbeating expectations. Total revenuesincreased 32% to$157.9 million as subscription services revenues rose 33% to $127.3 million whilenet incomeincreased 57% to $36.0million. The CEO commented:

  • [By Brian Stoffel]

    To say that Veeva Systems (NYSE:VEEV) has performed well as a publicly traded company would be an understatement. While the stock itself is actually down since its post-IPO days, the company’s fundamentals have vastly improved during that time frame.

Top 5 Clean Energy Stocks To Watch For 2018: National Steel Corporation(SID)

Advisors’ Opinion:

  • [By Lisa Levin]

    Basic materials shares climbed by 1.52 percent in trading on Friday. Meanwhile, top gainers in the sector included Companhia Siderurgica Nacional (ADR) (NYSE: SID), and Core Molding Technologies, Inc. (NYSE: CMT).

Top 5 Clean Energy Stocks To Watch For 2018: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

Top 5 Clean Energy Stocks To Watch For 2018: Actuant Corporation(ATU)

Advisors’ Opinion:

  • [By Monica Gerson]

    Actuant Corporation (NYSE: ATU) is projected to report its quarterly earnings at $0.18 per share on revenue of $267.64 million. Actuant shares dropped 3.73 percent to close at $22.98 yesterday.

  • [By Ben Levisohn]

    Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.

  • [By Monica Gerson]

    Actuant Corporation (NYSE: ATU) is estimated to report its quarterly earnings at $0.18 per share on revenue of $267.64 million.

    Jabil Circuit, Inc. (NYSE: JBL) is projected to post its quarterly earnings at $0.60 per share on revenue of $4.50 billion.

Top Stocks To Invest In Right Now

With Apple Inc. (Nasdaq: AAPL) reporting earnings after the bell tomorrow (Tuesday, May 2), investors will be closely watching the Apple cash reserves.

According to The Wall Street Journal, the Apple cash pile should total more than $250 billion, with more than 90% (or $225 billion) stashed overseas. That would further cement Apple’s status as the richest company on the planet. For comparison, those cash reserves are more than double Microsoft Corp.’s (Nasdaq: MSFT) $113 billion cash pile, according to Moody’s.

Money Morning Chief Investment Strategist Keith Fitz-Gerald stopped by FOX Business’ “Varney & Co.” to identify the three areas of Apple’s business where the company could put some of that cash to work if it brings it back into the United States.

Here’s more on what Fitz-Gerald calls Apple’s “three-pronged attack”…

This “Secret” Helped Transform Two Teachers into Millionaires: Today Donna and Dave R. are retired millionaires who are also earning $10,000 a month in income. Much of their wealth is due to a Great Depression-era “program” most have no idea exists. Learn more…

Top Stocks To Invest In Right Now: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

Top Stocks To Invest In Right Now: Western Union Company (The)(WU)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Western Union (WU) soared to the top of the S&P 500 today after MoneyGram International (MGI) received a bid from Euronet Worldwide (EEFT).

    Agence France-Presse/Getty Images

    Shares of Western Union gained 3.5% to $20.27 today, while the S&P 500 fell 0.3% to 2,365.45.MoneyGram International surged 25% to $15.77, while Euronet Worldwide advanced 0.3% to $83.22.

    Normally, two competitors linking up to take on the dominant player in the industry might be considered bad news. BTIG’s Mark Palmer and Giuliano Bolognaexplain why the Western Union reaction”makes sense”:

    While the surge in shares of MoneyGram (MGI, Not Rated) in response to the announcement by Euronet Worldwides (EEFT, Not Rated) that it had offered to buy the company for $15.20 per share in cash was easy to understand the bid trumped the bid of $13.25 per share that MoneyGram received from Alibaba (BABA) affiliate Ant Financial in late January what may have been surprising to some was the positive reaction of shares of MGI remittance competitor Western Union (WU, Buy, $23 PT) to the news.

    With that said, we believe the uptick in WU shares makes some sense insofar as the competitive threat posed by EEFT may be perceived as less imposing than that represented by Ant, especially following reports in February that the latter was planning to raise as much as $3bn to fund global investments.

    We also believe the second bid for MGI serves to underline the attractiveness and potential of the global remittance space, an industry in which WU is the clear leader. Moreover, we think the bid may have given rise to the notion that WU could be an acquisition candidate for another deep-pocketed firm that could lever off its global footprint and the strength of its brand.

    Western Union’s market capitalization rose to $9.8 billion today, from $9.4 billion yesterday. It reported net income of $253 million on sales of $5.4 billion in

  • [By WWW.THESTREET.COM]

    You don’t need to be an expert technical trader to figure out the price action in shares of $10 billion payment services stock Western Union (WU) . Instead, the price action is more or less as simple as it gets. Since January, Western Union has been a “buy the dips stock”, bouncing its way higher in a well-defined uptrend. And shares are showing traders another buyable dip this week.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was The Western Union Co. (NYSE: WU) which jumped 3.6% to $20.28. The stocks 52-week range is $18.07 to $22.70. Volume was 11 million which is well above the daily average of around 5.8 million shares.

  • [By Brian Mathews]

    Western Union Co. (NYSE: WU) is the leading independent provider of consumer money transfer services. After a rough couple of years and dealing with compliance and regulatory issues, WU has finally weathered the storm. Market share has stabilized and revenues have been slowly growing. One of Western Union’s strengths is its size in the industry. The money-transfer business is highly scalable because the incremental costs of processing additional transactions are minimal. This allows WU to have operating margins that are twice as large as its closest competitor. Also, since WU is a highly recognizable brand, consumers flock to use its services in comparison to its peers. Western Union submitted a bid to buy the Australian company OzForex. If this deal goes through, it will provide additional scale to WU, especially to a market clientele that is more affluent. With the troubling times behind the company and expansion on the horizon, expect WU stock to appreciate to $24.

Top Stocks To Invest In Right Now: Endologix, Inc.(ELGX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Endologix Inc. (NASDAQ: ELGX) dropped about 9.3% on Wednesday to post a new 52-week low of $4.78 against a 52-week high of $14.50 and a Tuesday close of $5.27. Volume of about 6 million was more than 3 times the daily average of around 1.7 million. The company on Tuesday announced a temporary shipping hold on its best-selling heart device, saying there was a manufacturing issue.

  • [By Lisa Levin]

    Endologix, Inc. (NASDAQ: ELGX) shares dropped 23 percent to $7.59 as the company issued an update on Nellix PMA process. Endologix disclosed that the FDA has requested the company to provide a two-year patient follow-up data from the EVAS-FORWARD IDE study of Nellix System.

Top Stocks To Invest In Right Now: WPX Energy, Inc.(WPX)

Advisors’ Opinion:

  • [By Money Morning News Team]

    WPX Energy Inc. (NYSE: WPX) is a natural gas and oil company based in Oklahoma. WPX focuses on the exploration and development of natural gas and oil fields in North America, including the Permian Basin in Texas and the Williston Basin in North Dakota.

  • [By Ezra Schwarzbaum]

    Matador has grown its reserves throughout the commodity cycle, as well as its production and cash flow. Haas also likes the company’s history of identifying and acquiring acreage early and cheaply. Much of the analyst’s positive outlook is derived from Matador’s successful monetization of midstream assets and pattern of reinvestment.

    WPX Energy Inc (NYSE: WPX), $18 Price Target

    Haas praised WPX’s production base, which is “well balanced” between three major basins, and its production mix of 51 percent oil, 13 percent natural gas liquids and 36 percent natural gas.

Top Stocks To Invest In Right Now: Transdigm Group Incorporated(TDG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    TransDigm Group (TDG) tumbled to the bottom of the S&P 500 today after Citron Research doubled down on its assertion that the company is a manufacturing version of Valeant Pharmaceuticals International (VRX).

    Agence France-Presse/Getty Images

    TransDigm Groupdropped 4.2% to $231.37, while the S&P 500 rose 0.3% to 2,372.60.

    From Citron’s report on TransDigm:

    Citron predicts that after this report makes its rounds, TransDigms (NYSE:TDG) days of exploiting and deceiving the Federal Government are numbered.

    Valeant Pharmaceuticals has recently hit prices lower than some ever thought was imaginable. As Citron observes today, at $12 per share, that stock is down over 95% from its highs just months prior to Citrons reporting on Philidor. The questions then turn to: How did so many smart people get it so wrong? and When could this possibly happen again?”

    While we are sure there will be many books written on these questions, we can narrow it down to a small checklist. The smart money got Valeant wrong by:

    Disregarding a roiling political climate disrupting “business as
    usual” Underestimating the financial frailty of a roll up Discounting the dangers of a small customer base (PBMs) Putting too much trust in the companys CEO…

    All points in the above checklist apply directly to TransDigm.

    TransDigm Group’s market capitalization fell to $12.2 billion today from $12.8 billion yesterday. It reported net income of $583 million on sales of $3.2 billion in 2016.

  • [By Lee Jackson]

    Transdigm Group Inc. (NYSE: TDG) had a director at the company step in and buy stock in a big way last week. That director purchased a total of 91,000 shares of the stock at prices ranging from $247.16 to $247.89. The total for the trade came in near $22.7 million.The company designs, produces and supplies aircraft components in the United States. Its stock closed trading last Friday at $251.488.

  • [By Ben Levisohn]

    TransDigm Group (TDG) soared to the top of the S&P 500 today after beating earnings and sales forecasts.

    Agence France-Presse/Getty Images

    TransDigm gained 6.5% to $245.88 today, while the S&P 500 finished little changed at2,293.08.

    TransDigm reported a profit of $2.57, beating forecasts for$2.47, on sales of $814 million, topping the Street consensus for $804.5 million.

    TransDigm’s market capitalization rose to $13.1 billion today from $12.3 billion yesterday.

  • [By Lee Jackson]

    Warren Buffett and Berkshire Hathaway were big buyers this week, as they added shares of aircraft components maker Transdigm Group Inc. (NYSE: TDG), forwhich they also serve as a director. Berkshire Hathaway bought 104,967 shares of the stock at prices that ranged from $231.18 to $234.40 per share. The total for the trade came in at a massive $25 million. The shares closed trading last Friday at $240.05, so the timing looks good. The 52-week trading range for the stock is $214.65 to $294.38. The Wall Street consensus price target is pegged at $295.24.

  • [By Mitchell Clark]

     This firm is not a household name. This Cleveland-based company, in the aerospace parts business, has approximately $12.0 billion in market capitalization on the stock market.

    TransDigm Group Incorporated (NYSE:TDG) doesn’t pay a regular dividend, but often pays out one-time, special dividends. In the past, they’ve been pretty hefty.

    Selling pumps, motors, power systems, and basically anything you can image that’s part of an aircraft, TDG’s been growing its financial results at a good clip.

  • [By Ben Levisohn]

    TransDigm (TDG) sunk to the bottom of the S&P 500 today after its earnings topped the Street consensus but its guidance disappointed.

    Shares of TransDigm fell 7.1% to $$252.96 today, while the S&P 500 finished little changed.

    TransDigm reported a profit of $3.29 a share, better than the $3.20 expect by analysts, on sales of$875.2 million, below forecasts for $884.26 million. Worse still, the airplane-part manufacturer said it would earn $11.84 to $12.12 a share in fiscal 2017, below forecasts for$12.80.

    TransDigm’s market cap fell to $13.5 billion today, from $14.5 billion on Friday.

learn about the stock market

The short interest ratio for Apple Inc. stock has spiked to a 3 month high while the days to cover metric has climbed over 2. Is AAPL stock setting up for a massive short squeeze?
Flickr

Apple (NASDAQ:AAPL) stock is off to a flying start in 2017. Shares of the Cupertino, California-basedtechnology giant are up nearly 22% in 2017, closing the trading session at a price of $140.88 per share. In comparison, the Nasdaq Composite (INDX:COMPX) is up 8.5% for the year while the S&P 500 (INDX:SPAL) has risen 4.6% in the same time frame. In other words, Apple stock has outperformed the broader market, and by a fair margin. Considering that we are only a quarter into the current year, the rise of AAPL stock hasn’t gone unnoticed. The short interest in Apple stock has risen steadily over the last few months, as the ‘bears’ expectation for a pullback has risen with every new high. Is it time to sell Apple stock? Or, is the AAPL stock still a good buy?

learn about the stock market: Ingles Markets Incorporated(IMKTA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Not all grocers will suffer from Amazon’s growing reach, but those who sell to high-income customers in the top 25 U.S. markets may see their business erode. Among those names include Costco (COST) , Trader Joe’s and Whole Foods (WFM) , which have the most to lose according to Barclays. On the other hand, Walmart (WMT) , Sam’s Club (owned by Walmart) and Ingle’s Markets (IMKTA)  have the least to lose.

learn about the stock market: (LGF.A)

Advisors’ Opinion:

  • [By Keith Noonan]

    While 2016 played host to a range of films that underperformed, the biggest flops belonged to Disney (NYSE:DIS), Viacom (NASDAQ:VIA) (NASDAQ:VIAB) and Lions Gate Entertainment (NYSE:LGF.A). Click through the presentation below to get the details on the year’s five biggest film flops and to learn what last year’s movie misfires mean for the companies involved.

learn about the stock market: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

learn about the stock market: CIRCOR International, Inc.(CIR)

Advisors’ Opinion:

  • [By Lisa Levin]

    CIRCOR International, Inc. (NYSE: CIR) was down, falling around 15 percent to $60.91. CIRCOR reported Q4 adjusted earnings of $0.48 per share on revenue of $158 million. Stifel Nicolaus downgraded Circor from Buy to Hold.